Catapres-TTS-2

The typical dosage for Catapres-TTS-2 is:

• Catapres-TTS-2 patch delivers 0.2 mg of clonidine per day. The patch is applied once every 7 days.

It's also been used to manage withdrawal symptoms from opioids, as part of a smoking cessation plan, and hot sweats

• The dose is decided by the healthcare provider based on individual conditions.

Catapres-TTS-2 is contraindicated in patients with:

• Hypersensitivity to clonidine or any components of the patch.
• Severe bradycardia (slow heart rate) or conditions where a further reduction in heart rate could be dangerous.

Patients using Catapres-TTS-2 should be advised to:

• Ensure proper application of the patch, rotating the application site weekly to prevent skin irritation.
• Replace the patch every 7 days at the same time and check that the patch remains securely in place.
• Avoid abruptly discontinuing the patch, as this can lead to a rapid increase in blood pressure (rebound hypertension). If the patch needs to be stopped, it should be tapered off under medical supervision.
• Be cautious about side effects like dizziness or drowsiness, especially when starting therapy, as clonidine can cause sedation and hypotension.
• Avoid using alcohol or sedative medications, as these may enhance the drowsiness caused by clonidine.
• 
  

• Drowsiness or fatigue
• Dry mouth
• Dizziness or lightheadedness (particularly when standing)
• Skin irritation or redness at the patch site

• Severe Bradycardia (Slow Heart Rate): Symptoms include fainting, dizziness, or extreme fatigue.
• Rebound Hypertension: If the patch is discontinued abruptly, blood pressure may rise significantly.
• Severe Skin Reactions: Such as rash, itching, or infection at the site of application.

Rebound Hypertension: Abrupt discontinuation of clonidine can cause a dangerous spike in blood pressure. If the patch needs to be stopped, it should be done gradually under medical supervision.

Sedation and Drowsiness: Clonidine can cause drowsiness, especially when starting treatment or increasing the dose. Patients should avoid activities requiring full alertness, such as driving, until they know how the medication affects them.

Hypotension and Bradycardia: Clonidine can cause a significant reduction in blood pressure and heart rate. Patients should be monitored for signs of hypotension and bradycardia, especially during the initial phase of treatment.

Catapres-TTS-2 may interact with other medications, including:

• Antihypertensive Medications: Combining clonidine with other blood pressure-lowering drugs (e.g., beta-blockers or diuretics) can increase the risk of low blood pressure and slow heart rate.
• Sedatives and Alcohol: These can increase the sedative effects of clonidine, leading to excessive drowsiness.
• Tricyclic Antidepressants: These may reduce the effectiveness of clonidine in controlling blood pressure.

Patients should inform their healthcare provider of all medications and supplements they are taking to avoid potential interactions.

Alternative treatments for hypertension include:

• Other Alpha-2 Adrenergic Agonists: Such as guanfacine, which works similarly to clonidine.
• Beta-Blockers: Such as atenolol or metoprolol, which lower blood pressure by reducing heart rate.
• ACE Inhibitors: Such as lisinopril or enalapril, used to lower blood pressure by relaxing blood vessels.
• ARBs (Angiotensin II Receptor Blockers): Such as losartan or valsartan, used for hypertension management.
• Calcium Channel Blockers: Such as amlodipine, which help relax blood vessels to lower blood pressure.